Clinical trials: HBV Reactivation
HBV
HBV Reactivation in Immunocompromised Patients (REANT STUDY)
Background/Objective: Comorbidities represent a critical risk factor in the prognosis of patients receiving immunosuppressive therapy.
- Trial name
- NCT07529171
- Testing
- Antiviral
- Where
- 16 sites in Turkey (Türkiye)
- Volunteers
- 490 people
- Sponsor
- Yaşar Bayındır, MD
Hepatitis B Reactivation
TDF and Entekavir - Hepatitis B Reactivation
This is a non-interventional retrospective multi-center study for the patients received Entekavir or TDF for Hepatitis B prophylaxis.
- Trial name
- NCT06049602
- Where
- Turkey (Türkiye)
- Volunteers
- 10,000 people
- Sponsor
- Viral Hepatitis Society
Non-Hodgkin Lymphoma, Hepatitis B Reactivation
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
The aim of this study is to prove the superiority of entecavir over lamivudine for preventing the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on CHOP/R-CHOP.
- Trial name
- NCT01914744
- Testing
- Entecavir, Lamivudine
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Fudan University
Hepatitis, Hepatitis B
Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients
This study is a retrospective analysis to explore the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the efficacy and safety of chemotherapy, and overall survival rate in lymphoma…
- Conditions
- Hepatitis, Hepatitis B, Lymphoma, Hematologic Diseases
- Trial name
- NCT02108444
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Peking University
Reactivation of Hepatitis B Virus
Chemotherapy Efficacy and Follow-up Study of Hepatitis B Virus Infection and Reactivation in Children With Leukemia
Children with clinically diagnosed leukemia may experience occult HBV infection after chemotherapy immunosuppressive therapy, which may affect the normal course of leukemia treatment.
- Trial name
- NCT03529760
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Chongqing Medical University
Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide
In this study, we will evaluate the incidence of hepatitis B virus reactivation within the first 6 months of treatment with rituximab, standard chemotherapy and TAF in patients with diffuse Large B-Cell Lymphoma/Chronic Lymphoid…
- Trial name
- CLL1818 (NCT03804372)
- Testing
- Rituximab, Chemotherapy, Tenofovir alafenamide
- Where
- 31 sites in Italy
- Volunteers
- 5 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
HBV (Hepatitis B Virus), HIV Infection
Occult Hepatitis B Virus Infection and HBV Reactivation After Switching to Long Acting Therapy in Patients With HIV-1
The primary objective of the present project will be to investigate the risk of HBV reactivation (from virological reactivation to overt HBV infection) in HIV-1 carriers with occult HBV infection (OBI, is characterized by the…
- Trial name
- OBILART (NCT06728917)
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Hepatocellular Carcinoma
Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study
Immune checkpoint inhibitor (ICI), including programmed cell death protein-1 (PD-1) inhibitor or programmed cell death-Ligand 1 (PD-L1) inhibitor , is recommended to treat advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT04680598
- Testing
- ICI, Antiviral Prophylaxis
- Where
- 4 sites in China
- Volunteers
- 800 people
- Sponsor
- Sun Yat-sen University
Exposure to Hepatitis B Virus
Risk of Hepatitis B Reactivation After Bone Marrow Transplantation With Prior Hepatitis B Virus (HBV) Exposure
The purpose of this study is to determine whether preemptive nucleoside analogue therapy or regular virologic monitoring is the preferred method in management patients with prior exposure to hepatitis B vius (HBV) and undergoing…
- Trial name
- NCT01481649
- Where
- Hong Kong
- Volunteers
- 69 people
- Sponsor
- The University of Hong Kong
Hepatitis B
HBV Reactivation in Anti CD20 Treatment
The goal of this observational study is to test and describe the frequency of hepatitis B virus reactivation in patients who received anti-CD20 drugs for a wide variety of autoimmune and hemato-oncological diseases in order to…
- Trial name
- NCT05768061
- Where
- Israel
- Volunteers
- 5,000 people
- Sponsor
- HaEmek Medical Center, Israel
Lymphoma, B-Cell, Marginal Zone
Marginal Zone Lymphoma Cohort in Korea
Marginal zone lymphoma is a rare of subtype of Non-Hodgkin Lymphoma. Because of its rarity, prospective clinical trial is difficult to conduct.
- Trial name
- NCT02732236
- Testing
- Rituximab
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Dong-A University Hospital
Exposure to Hepatitis B Virus
Risk of Hepatitis B Reactivation in Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy: A Prospective Study
The purpose of this study is to determine whether preemptive nucleoside analogue therapy or regular virologic monitoring is the preferred method in management patients with prior exposure to hepatitis B vius (HBV) and undergoing…
- Trial name
- NCT01502397
- Where
- Hong Kong
- Volunteers
- 70 people
- Sponsor
- The University of Hong Kong
Hepatitis B
Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection
Background: Treatment of some diseases can suppress the immune system. This can cause other conditions to reactivate. Recent cases have shown that hepatitis B virus (HBV) reactivates in people who had already recovered from it…
- Trial name
- NCT03248622
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B, Chronic, Tumor
Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy
To evaluate the effectiveness and safety of tenofovir for different treatment duration in preventing HBV relapse in patients with malignancies after receiving chemotherapy and off-treatment of chemotherapy.
- Trial name
- NCT02081469
- Testing
- TDF
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Chang Gung Memorial Hospital
Acute on Chronic Liver Failure, Hepatitis B
Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure
Background: Reactivation of hepatitis B is a well-characterized syndrome marked by the abrupt reappearance or rise of hepatitis B virus (HBV) DNA in the serum of a patient with previously inactive or resolved HBV infection.
- Trial name
- ACLF (NCT01074645)
- Testing
- Tenofovir disoproxil fumarate (TDF)
- Where
- India
- Volunteers
- 27 people
- Sponsor
- Govind Ballabh Pant Hospital
Non-Hodgkin's Lymphoma
A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen
AIMS OF THE STUDY (STUDY OBJECTIVES) 1. To test the effect of daily lamivudine (100 mg) in reducing the risk of HBV reactivation and hepatitis development in HBsAg (+) NHL patients. 2.
- Trial name
- NCT00201318
- Testing
- Cyclophosphamide Doxorubicin Vincristine Lamivudine
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Liver Cancer
Effects of Antiviral Therapy on HBV Reactivation
Hepatitis B virus (HBV) reactivation happens after liver resection for HBV-related hepatocellular carcinoma (HCC) patients, particularly for those with positive serum HBV-DNA .
- Trial name
- HBV-DNA(-) (NCT02829359)
- Testing
- Entecavir therapy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Rheumatoid Arthritis, Hepatitis B Reactivation
Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients
Antiviral prophylaxis can prevent the risk of biologic agents-associated HBV reactivation in hepatitis B inactive carriers and patients with past HBV infection
- Conditions
- Rheumatoid Arthritis, Hepatitis B Reactivation, Exposure to Hepatitis B Virus
- Trial name
- NCT01907230
- Testing
- Entecavir
- Where
- Taiwan
- Volunteers
- 115 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Chronic Hepatitis B, Rheumatoid Arthritis
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
Analysis of effect of anti-TNFα treatment on HBV reactivation among patients with systemic rheumatic disease, especially rheumatoid arthritis
- Conditions
- Chronic Hepatitis B, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01694264
- Testing
- Entecavir
- Where
- 22 sites in South Korea
- Volunteers
- 43 people
- Sponsor
- Seoul National University Hospital
HBV Reactivation, HSCT
HBV Reactivation Prediction Model in Allo-HSCT
Hepatitis B virus (HBV) reactivation is a serious complication after allogeneic haematopoietic stem cell transplantation (allo-HSCT), particularly in patients with resolved HBV infection (HBsAg-negative, anti-HBc-positive).
- Trial name
- HBV-post HSCT (NCT07644026)
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 300 people
- Sponsor
- Xiao Hui Zhang